Cambridge Investment Research Advisors
CINC

Cambridge Investment Research Advisors’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CINC Stock Details CINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,225
Closed -$150K – 3301
2022
Q4 		$150K Buy
12,225
+6,000
+96% +$143K ﹤0.01% 2834
2022
Q3 		$204K Buy
+6,225
New +$176K ﹤0.01% 2690

Cambridge Investment Research Advisors's CINC Position: Q1 2023 in Review

Cambridge Investment Research Advisors sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 12,225 shares — an estimated $150K sold.

Cambridge Investment Research Advisors first reported a position in CINC in Q3 2022 and held it in 2 quarters. The position peaked at $204K in Q3 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

  • Cambridge Investment Research Advisors reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 12,225 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $150K.
  • Cambridge Investment Research Advisors first reported a position in CinCor Pharma, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's CinCor Pharma, Inc. Common Stock position peaked at $204K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2023, filed 11 May 2023.